



ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

11th Annual Course

Barcelona, Spain

March 23rd - 24th, 2012

Chair:

C. Bokemeyer, H. Ludwig, P. Gascon

Course co-ordinator:

M. Aapro

In collaboration with



EORTC
European Organisation for Research
and Treatment of Cancer

Anaemia Working Party

ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

Friday, March 23rd, 2012

PROGRAM

- 10:00 Registrations Open
- 12:00-13:00 Buffet Lunch
- 13:00-13:10 **Welcome:** Chairmen and Coordinator
- 13:10-13:30 **SESSION 1: Anaemia in Cancer Patients**
Chairman: *H. Ludwig*
- 13:10-13:30 Pathophysiology and incidence of anaemia in cancer patient
T. Littlewood
- 13:35-14:50 **SESSION 2: Neutropenia in Cancer Patients**
Chairman: *M. Aapro*
- 13:35-13:50 EORTC guidelines for G-CSF usage. Any unsolved issues? Are they followed? - *M. Aapro*
- 13:55-14:10 Why do patients have pain with G-CSF - *P. Pronzato*
- 14:15-14:30 Models for FN risk assessment - *R. Pettengell*
- 14:35-14:50 What to do if FN hits: patient evaluation and empirical antibiotics
J. Muñoz
- 14:55-15:45 **SESSION 3: Anaemia Management in Cancer Patients**
Chairman: *M. Dicato*
- 14:55-15:15 Safety and efficacy of red blood cell transfusions - *A. Hofmann*
- 15:20-15:45 New avenues of research to fight anaemia? Which are the drugs on the horizon? - *J. Glaspy*
- 15:50-16:25 **BREAK**
- 16:30-17:35 **SESSION 4: Iron and Cancer Patients**
Chairman: *H. Ludwig*
- 16:30-16:50 Pathophysiology of iron deficiency in cancer patients and the role of hepcidin - *Y. Béguin*
- 16:55-17:15 Iron deficiency in cancer patients: what to do in daily practice?
H. Ludwig

THROMBOCYTOPENIA AND CANCER COURSE

Friday, March 23rd, 2012

- 17:20-17:35 Are there concerns about iron use? - *A. Österborg*
- 17:40-18:55 **SESSION 5: Thrombosis**
Chairman: *M. Mandala*
- 17:40-18:00 Incidence and pathophysiology of thrombosis in cancer patients
C. Ay
- 18:05-18:30 LMWH: prophylaxis, therapy or survival: a critical review of the
current evidence - *M. Mandala*
- 18:35-18:55 Anti-Xa in oncology - *J. C. Reverter*
- 19:00 Closure of the day

Saturday, March 24th, 2012

- 08:40-09:25 **SESSION 6: About EPO in 2012**
Chairman: *P. Gascon*
- 08:40-08:55 Early EPO intervention, better result, less loss - *P. Gascon*
- 09:00-09:30 A debate about EPO: ESAs used per guidelines are safe
- 09:00 Vote from the floor
- 09:05-09:15 In favour - *M. Apro*
- 09:15-09:25 Against - *M. Dicato*
- 09:25 Vote from the floor
- 09:30-10:05 **SESSION 7: Biosimilars: manufacturing and health cost
implications**
Chairman: *M. Dicato*
- 09:30-09:45 Process changes in manufacturing biologics and what is the
position of the regulators? - *H. Schellekens*
- 09:50-10:05 How to manage the rising cost in oncology? - *P. Cornes*
- 10:10-10:40 **BREAK**

THROMBOCYTOPENIA AND CANCER COURSE

Objectives of the course

This course should clarify issues related to anaemia and neutropenia in the cancer patient and the optimal way of preventing or treating these problems, including a review of EORTC guidelines for anaemia and neutropenia management. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron, discussed with participation from the audience. At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients and critically follow the development of this important field in the near future.

Official language

The official language of the course is English

CME information

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference. The CME certificates can be granted only to the participants who have attended the entire conference. The CME certificates will be distributed only at the end of the meeting.

Organising secretariat

Vision Plus Srl
P.zza San Pietro Martire, 6 - 20900 Monza (MB) - Italy
Phone +39 039 2326183 - Fax +39 039 3309918
Email: medicaleducation@visionplus.it

ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

GENERAL INFORMATION

Course venue

Hotel Barcelò Sants
Plaça dels Països Catalans, s/n
08014 Barcelona, Spain
Phone: +34 93 5035300

Topics covered during the course

- **Basic facts about anaemia, neutropenia and thrombocytopenia**
Short review of normal myelopoiesis
Pathophysiology of anaemia in cancer
Incidence of anaemia in cancer
Importance of neutropenia in cancer
Importance of thrombocytopenia in cancer
- **Symptoms and consequences of anaemia, neutropenia and thrombocytopenia**
Clinical symptoms - quality of life
Consequences of anaemia on tumour progression and prognosis
Consequences of neutropenia
Consequences of thrombocytopenia
- **Treatment of anaemia and neutropenia in cancer patients**
Predicting risk of anaemia during chemotherapy
Transfusions: pros and cons
Erythropoietin and iron:
 - Clinical results
 - Impact on haemoglobin
 - Impact on transfusion frequency
 - Impact on quality of life
 - Impact on outcome
 - Prediction of response
 - Economic aspects and biosimilars
 - How to use them properlyUpdated EORTC G-CSF use guidelines
- **Present and future developments**
Developments in immune thrombocytopenic purpura: any relevance for oncology?

THROMBOCYTOPENIA AND CANCER COURSE

Objectives of the course

This course should clarify issues related to anaemia and neutropenia in the cancer patient and the optimal way of preventing or treating these problems, including a review of EORTC guidelines for anaemia and neutropenia management. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron, discussed with participation from the audience. At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients and critically follow the development of this important field in the near future.

Official language

The official language of the course is English

CME information

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference.
The CME certificates can be granted only to the participants who have attended the entire conference.
The CME certificates will be distributed only at the end of the meeting.

Organising secretariat

Vision Plus Srl
P.zza San Pietro Martire, 6 - 20900 Monza (MB) - Italy
Phone +39 039 2326183 - Fax +39 039 3309918
Email: medicaleducation@visionplus.it